Results 271 to 280 of about 2,261,771 (384)
Hafnium (Hf)‐rich carbon dots (Hf‐rCDs) with high metal content (40.7%) and robust batch production capacity (>2 g per batch) are synthesized via a facile air‐assisted pyrolysis method. In vivo CT imaging demonstrates outstanding performance of Hf‐rCDs across multiple physiological systems and enables high‐resolution visualization of swine cervical ...
Shuo Li +11 more
wiley +1 more source
Prior-Night Sleep as an Event-Level Predictor of Alcohol-Induced Memory Loss. [PDF]
Merrill JE +5 more
europepmc +1 more source
6 nm iron oxide nanoparticles (IONP6) exhibit enzyme‐like activities that scavenge reactive oxygen and nitrogen species (RONS), including nitric oxide (NO). In stroke models, IONP6 promotes microglial polarization toward the M2 phenotype, reduces neuroinflammation, and improves neurological outcomes, offering a promising drug‐free approach to mitigate ...
Yilin Qi +12 more
wiley +1 more source
Structural brain recovery following reductions in adolescent and young adult binge drinking: A longitudinal NCANDA study. [PDF]
Gonzalez MR +18 more
europepmc +1 more source
Higher plasma leucine is associated with increased risk of new‐onset myocardial infarction. Leucine deprivation alleviates advanced atherosclerosis in mice. Tumor‐induced leucine deprivation reprograms macrophage metabolism and increases CD5Lhi macrophages in mouse plaques. Mechanistically, leucine deficiency reduced SLC7A5‐PGAM5 binding in macrophages,
Shan Zhong +22 more
wiley +1 more source
Effects of at-risk drinking on central hemodynamics and aortic stiffness in midlife adults. [PDF]
Chang KY +9 more
europepmc +1 more source
This research provides the first comprehensive evidence that PS‐MPs exacerbate ccRCC progression by activating the NF‐κB and TGF‐β pathways. These findings establish PS‐MPs as an environmental risk factor for ccRCC progression and identify the NF‐κB and TGF‐β signaling as potential therapeutic targets to mitigate the adverse effects of ‐PS‐MPs exposure.
Shiqi Ye +18 more
wiley +1 more source
Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials: A Review. [PDF]
Witkiewitz K +7 more
europepmc +1 more source

